Navigation Links
Cardiva Medical, Inc. to Present at the 'Investment In Innovation (In3) Medical Device Summit' on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
Date:6/16/2008

MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System announces that it will present the initial market results of the Boomerang Catalyst(TM) II System and completion of its US sales force expansion on June 18 at 3:20pm at the Medtech Insight/Windhover Information's "Investment In Innovation (In3) Medical Device Summit" medical technology investment and partnering conference held at The Palace Hotel in San Francisco, CA.

The Boomerang Catalyst II System is Cardiva's second-generation vascular closure device that employs proprietary hemostatic coatings to accelerate hemostasis in the cardiac catheterization lab following endovascular procedures. This unique technology leaves absolutely nothing behind in the patient, thereby eliminating a major source of complications.

In April 2008, Cardiva Medical, Inc. completed a $15.5 million private equity financing. With the financing proceeds, Cardiva has aggressively recruited and completed the expansion of its direct sales forces in the US to 72 professionals including 21 territory managers, 36 clinical educators, and 15 sales managers.

"Since the product launch of the Boomerang Catalyst II System about six months ago, we have received very positive feedback from physicians, and experienced rapid adoption of the Boomerang Catalyst II technology in the cardiac catheterization labs across the country," commented Augustine Y. Lien, Chairman and CEO. "With the infusion of more than $15 million from our recent equity financing, we have successfully doubled our direct sales force in the past two months, allowing Cardiva to establish a visible presence in all the major metropolitan areas in the US and enabling greater access to the vast opportunity in the vascular access closure market."

About Cardiva Medical, Inc.

Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing devices which close the vascular access site with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at http://www.cardivamedical.com.

Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.

Media Contact:

Glenn Foy, President

Cardiva Medical, Inc.

Phone: 650.964.8900, x 215

Fax: 650.964.8911

glenn_foy@cardivamedical.com


'/>"/>
SOURCE Cardiva Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
4. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
5. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
6. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
7. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
8. Medical, Behavioral Woes Can Drive Dogs to Bite
9. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
10. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
11. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: